Advent firms up deal for Sanofi in Europe

Advent International and Sanofi have struck a final deal for the private-equity investment group to acquire Sanofi’s European generics business, Zentiva, through a share purchase agreement worth €1.9 billion (US$2.2 billion). The deal comes after the completion of exclusive negotiations that were announced by the two companies in mid-April (Generics bulletin, 20 April 2018, page 1).